Increasing global regulation of drug prices and expenditures already affects the efficiency of pharmaceutical R&D and of health care delivery, with important implications for patient care now and in the future. The author examines the effect of existing foreign regulation - price controls, rate-of-return regulations, and industrial policies - on U.S. and other multinational producers of innovative drugs. She explores the growing threat to global revenues from the regulatory use of international price comparisons and the increasing threat from parallel trade.
"synopsis" may belong to another edition of this title.
Danzon is the Celia Moh Professor of Health Care Systems and Insurance at the Wharton School, University of Pennsylvania. She is also an adjunct scholar of the American Enterprise Institute.
"About this title" may belong to another edition of this title.
Book Description National Book Network. Book Condition: New. Brand New. Bookseller Inventory # 0844739839
Book Description Aei Press. PAPERBACK. Book Condition: New. 0844739839 *BRAND NEW* Ships Same Day or Next!. Bookseller Inventory # NATARAJB1FI955789
Book Description Aei Press, 1998. Paperback. Book Condition: New. Bookseller Inventory # DADAX0844739839